Roivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 414,683 Shares

Roivant Sciences Ltd. (NASDAQ:ROIV) CEO Eric Venker sold 414,683 shares of the business’s stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $16.93, for a total value of $7,020,583.19. Following the completion of the sale, the chief executive officer owned 1,504,959 shares in the company, valued at $25,478,955.87. This represents a 21.60% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Eric Venker also recently made the following trade(s):

• On Friday, October 17th, Eric Venker sold 118,418 shares of Roivant Sciences stock. The shares were sold at an average price of $17.06, for a total value of $2,020,211.08.
• On Thursday, October 16th, Eric Venker sold 318,282 shares of Roivant Sciences stock. The shares were sold at an average price of $17.05, for a total value of $5,426,708.10.
• On Monday, October 13th, Eric Venker sold 20,727 shares of Roivant Sciences stock. The shares were sold at an average price of $16.25, for a total value of $336,813.75.
• On Thursday, October 9th, Eric Venker sold 104,940 shares of Roivant Sciences stock. The shares were sold at an average price of $16.30, for a total value of $1,710,522.00.
• On Wednesday, October 8th, Eric Venker sold 138,602 shares of Roivant Sciences stock. The shares were sold at an average price of $16.20, for a total value of $2,245,352.40.
• On Monday, October 6th, Eric Venker sold 171,396 shares of Roivant Sciences stock. The shares were sold at an average price of $16.34, for a total value of $2,800,610.64.
• On Tuesday, October 7th, Eric Venker sold 355,161 shares of Roivant Sciences stock. The stock was sold at an average price of $16.15, for a total value of $5,735,850.15.
• On Tuesday, September 23rd, Eric Venker sold 611,000 shares of Roivant Sciences stock. The stock was sold at an average price of $14.83, for a total value of $9,061,130.00.
• On Monday, September 22nd, Eric Venker sold 416,182 shares of Roivant Sciences stock. The stock was sold at an average price of $14.99, for a total value of $6,238,568.18.
• On Friday, September 19th, Eric Venker sold 683,818 shares of Roivant Sciences stock. The stock was sold at an average price of $14.95, for a total value of $10,223,079.10.

Roivant Sciences Price Performance

Shares of NASDAQ ROIV opened at $17.26 on Friday. The stock’s 50-day moving average is $13.97 and its two-hundred day moving average is $12.01. Roivant Sciences Ltd. has a 1-year low of $8.73 and a 1-year high of $17.33. The company has a market cap of $11.79 billion, a price-to-earnings ratio of -24.66 and a beta of 1.20.

Wall Street Analysts Forecast Growth

ROIV has been the topic of several recent research reports. The Goldman Sachs Group upped their price target on Roivant Sciences from $20.00 to $24.00 and gave the stock a “buy” rating in a report on Thursday, September 18th. Weiss Ratings restated a “sell (d+)” rating on shares of Roivant Sciences in a report on Wednesday, October 8th. Citigroup assumed coverage on Roivant Sciences in a research report on Tuesday, September 2nd. They set a “buy” rating and a $16.00 price objective for the company. Bank of America upped their price objective on Roivant Sciences from $12.00 to $16.50 and gave the stock a “neutral” rating in a research report on Thursday, September 18th. Finally, HC Wainwright upped their price objective on Roivant Sciences from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Thursday, September 18th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $19.94.

Institutional Trading of Roivant Sciences

A number of large investors have recently made changes to their positions in ROIV. Perceptive Advisors LLC acquired a new stake in shares of Roivant Sciences in the 2nd quarter valued at about $37,546,000. Nuveen LLC acquired a new stake in shares of Roivant Sciences in the 1st quarter valued at about $31,988,000. Orbimed Advisors LLC acquired a new stake in shares of Roivant Sciences in the 2nd quarter valued at about $31,324,000. Rubric Capital Management LP boosted its position in shares of Roivant Sciences by 14.7% in the 2nd quarter. Rubric Capital Management LP now owns 20,370,336 shares of the company’s stock valued at $229,574,000 after purchasing an additional 2,603,260 shares during the period. Finally, Squarepoint Ops LLC boosted its position in shares of Roivant Sciences by 2,580.0% in the 2nd quarter. Squarepoint Ops LLC now owns 2,211,675 shares of the company’s stock valued at $24,926,000 after purchasing an additional 2,129,150 shares during the period. 64.76% of the stock is owned by institutional investors and hedge funds.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.